Blair William & Co. IL Reduces Position in Twist Bioscience Co. (NASDAQ:TWST)

Blair William & Co. IL cut its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 22.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,946 shares of the company's stock after selling 19,355 shares during the period. Blair William & Co. IL owned approximately 0.11% of Twist Bioscience worth $3,157,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Van ECK Associates Corp lifted its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after acquiring an additional 267 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $34,000. US Bancorp DE lifted its stake in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC purchased a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $95,000. Finally, KBC Group NV increased its position in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have issued reports on TWST shares. Robert W. Baird boosted their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. Barclays set a $58.00 price objective on Twist Bioscience and gave the company an "overweight" rating in a report on Monday, February 3rd. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Guggenheim set a $50.00 target price on shares of Twist Bioscience in a research note on Friday, March 28th. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus target price of $54.10.

Remove Ads

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares of the company's stock, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dennis Cho sold 806 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the transaction, the insider now owns 112,221 shares of the company's stock, valued at $5,538,106.35. This represents a 0.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,682 shares of company stock valued at $1,582,011. 3.01% of the stock is currently owned by corporate insiders.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded down $1.31 during mid-day trading on Friday, reaching $36.19. 2,398,396 shares of the stock traded hands, compared to its average volume of 957,093. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average of $43.80 and a 200 day moving average of $45.08. The stock has a market capitalization of $2.16 billion, a PE ratio of -10.71 and a beta of 2.34. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period in the previous year, the business posted ($0.75) earnings per share. Twist Bioscience's quarterly revenue was up 24.1% on a year-over-year basis. On average, analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.